Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTI-1: HDV-Insulin Lispro Dosing Algorithms in T1DM
NCT03938740Phase 2Completed
- Sponsor
- Diasome Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HDV-Insulin Lispro in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Diasome Pharmaceuticals. Primary endpoints: Basal insulin dose at 24 weeks, Bolus insulin dose at 24 weeks and 2 more. Started Mar 2019; status: completed.
02
Drugs
HDV-Insulin Lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03938740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938740.